Crispr Therapeutics (NASDAQ:CRSP) and Organovo (NASDAQ:ONVO) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, institutional ownership and valuation.
Earnings & Valuation
This table compares Crispr Therapeutics and Organovo’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Crispr Therapeutics||$3.12 million||860.13||-$164.98 million||($3.44)||-14.74|
|Organovo||$3.09 million||17.84||-$26.64 million||($0.23)||-1.84|
This table compares Crispr Therapeutics and Organovo’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Crispr Therapeutics has a beta of 3.11, meaning that its stock price is 211% more volatile than the S&P 500. Comparatively, Organovo has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500.
This is a summary of recent ratings and target prices for Crispr Therapeutics and Organovo, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Crispr Therapeutics currently has a consensus price target of $56.00, indicating a potential upside of 10.41%. Organovo has a consensus price target of $2.50, indicating a potential upside of 490.74%. Given Organovo’s stronger consensus rating and higher possible upside, analysts clearly believe Organovo is more favorable than Crispr Therapeutics.
Insider and Institutional Ownership
48.9% of Crispr Therapeutics shares are owned by institutional investors. Comparatively, 39.4% of Organovo shares are owned by institutional investors. 21.4% of Crispr Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Organovo shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Crispr Therapeutics beats Organovo on 8 of the 14 factors compared between the two stocks.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The company is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, it is developing allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; CTX120, a CAR-T cell product candidate for the treatment of multiple myeloma; CTX130 for the treatment of solid tumors and hematologic malignancies; programs to treat Hurler Syndrome and severe combined immunodeficiency disease, as well as glycogen storage disease Ia; and programs targeting diseases, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreements with Vertex Pharmaceuticals, Incorporated and Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use various therapeutics; and StrideBio LLC to develop adeno-associated viral capsids. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer; ViaCyte, Inc. for designing, developing, and commercializing gene-edited allogeneic stem cell therapies for the treatment of diabetes; and ProBioGen AG to develop novel in vivo delivery modalities for CRISPR/Cas9. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
Organovo Holdings, Inc., a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat a range of rare, life-threatening diseases. In addition, the company offers preclinical in vitro disease modeling platforms, including a range of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis conditions. Further, it involved in various programs to develop its NovoTissues transplantable tissues to address various serious unmet medical needs in adult and pediatric populations primarily focusing on liver disease. The company was founded in 2007 and is headquartered in San Diego, California.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.